Therapeutic Potential of GSK-J4, a Histone Demethylase KDM6B/JMJD3 Inhibitor, for Acute Myeloid Leukemia

Journal of Cancer Research and Clinical Oncology - Germany
doi 10.1007/s00432-018-2631-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Pharmacological Role of Histone Demethylase JMJD3 Inhibitor GSK-J4 on Glioma Cells

Oncotarget
Oncology
2017English

Antiproliferative Effect of the Histone Demethylase Inhibitor GSK-J4 in Chondrosarcomas

IUBMB Life
BiochemistryGeneticsClinical BiochemistryCell BiologyMolecular Biology
2019English

Human Histone Demethylase KDM6B Can Catalyse Sequential Oxidations

Chemical Communications
SurfacesAlloysMaterials ChemistryCoatingsMetalsOpticalMagnetic MaterialsFilmsCatalysisChemistryElectronicCompositesCeramics
2018English

A Novel, Dual Pan-Pim/Flt3 Inhibitor SEL24 Exhibits Broad Therapeutic Potential in Acute Myeloid Leukemia

Oncotarget
Oncology
2018English

Structural Basis of Histone Demethylase KDM6B Histone 3 Lysine 27 Specificity

English

The Histone Demethylase KDM6B Regulates Temperature-Dependent Sex Determination in a Turtle Species

Science
MultidisciplinaryPhilosophy of ScienceHistory
2018English

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

Histone Demethylase Jmjd3 Regulates Osteoblast Differentiation via Transcription FactorsRunx2and Osterix

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2013English

Histone Demethylase JMJD3 Contributes to Epigenetic Control of INK4a/ARF by Oncogenic RAS

Genes and Development
GeneticsDevelopmental Biology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy